Summit Therapeutics Inc.SMMTNASDAQ
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average, modest growth trend.
Left:
||||
Year-over-year operating income growth rate
Latest
58.80%
↑ 174% above average
Average (39q)
-79.39%
Historical baseline
Range
High:454.64%
Low:-2546.21%
CAGR
+3.5%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 58.80% |
| Q2 2025 | -750.30% |
| Q1 2025 | -1.89% |
| Q4 2024 | -12.91% |
| Q3 2024 | 2.52% |
| Q2 2024 | -40.64% |
| Q1 2024 | -49.24% |
| Q4 2023 | -38.61% |
| Q3 2023 | -29.75% |
| Q2 2023 | 97.06% |
| Q1 2023 | -2546.21% |
| Q4 2022 | -19.83% |
| Q3 2022 | -33.47% |
| Q2 2022 | 42.72% |
| Q1 2022 | 14.93% |
| Q4 2021 | -33.67% |
| Q3 2021 | 17.88% |
| Q2 2021 | -40.22% |
| Q1 2021 | -24.90% |
| Q4 2020 | 20.02% |
| Q3 2020 | -36.70% |
| Q2 2020 | -32.69% |
| Q1 2020 | -56.58% |
| Q4 2019 | 39.91% |
| Q4 2019 | -32.54% |
| Q3 2019 | -20.48% |
| Q2 2019 | 15.56% |
| Q1 2019 | 38.06% |
| Q4 2018 | -136.95% |
| Q3 2018 | 454.64% |
| Q2 2018 | 14.41% |
| Q1 2018 | -54.35% |
| Q4 2017 | -20.22% |
| Q3 2017 | 23.05% |
| Q2 2017 | 8.98% |
| Q1 2017 | -26.36% |
| Q4 2016 | 33.01% |
| Q3 2016 | -6.69% |
| Q2 2016 | -27.38% |
| Q1 2016 | 15.39% |